Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
- Evaluated articles (Rapid Reviews Infectious Diseases)
Abstract
Article activity feed
-
SciScore for 10.1101/2020.10.15.20209817: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: OVERSIGHT AND FUNDING: The trial is registered (ISRCTN83971151, NCT04315948), with protocol approved by local and WHO ethics committees.
Consent: The only exclusions were patients without clear consent to follow-up.Randomization Participants were randomized in equal proportions between control and whichever other study drugs were locally available (up to 5 options: these drugs, and local standard-of-care). Blinding SAMPLE SIZE: The protocol stated “The larger the number entered the more accurate the results will be, but numbers entered will depend on how the epidemic develops… it may be possible to enter several thousand hospitalised patients with relatively … SciScore for 10.1101/2020.10.15.20209817: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement IRB: OVERSIGHT AND FUNDING: The trial is registered (ISRCTN83971151, NCT04315948), with protocol approved by local and WHO ethics committees.
Consent: The only exclusions were patients without clear consent to follow-up.Randomization Participants were randomized in equal proportions between control and whichever other study drugs were locally available (up to 5 options: these drugs, and local standard-of-care). Blinding SAMPLE SIZE: The protocol stated “The larger the number entered the more accurate the results will be, but numbers entered will depend on how the epidemic develops… it may be possible to enter several thousand hospitalised patients with relatively mild disease and a few thousand with severe disease, but realistic, appropriate sample sizes could not be estimated at the start of the trial.” The Executive Group, blind to any findings, decided the timing of release of interim results. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04315948 Active, not recruiting Trial of Treatments for COVID-19 in Hospitalized Adults NCT04385095 Recruiting Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-1… NCT04492475 Completed Adaptive COVID-19 Treatment Trial 3 (ACTT-3) ISRCTN83971151 NA NA Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
-
Emily Walsh
Review 4: "Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results"
This reliable study suggests four antivirals have no effect on important clinical outcomes in hospitalized COVID-19 patients. While the randomized control trial is thorough, reviewers note missing descriptions of study protocol, patient eligibility, & adverse reactions.
-
Stephen Shiboski
Review 3: "Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results"
This reliable study suggests four antivirals have no effect on important clinical outcomes in hospitalized COVID-19 patients. While the randomized control trial is thorough, reviewers note missing descriptions of study protocol, patient eligibility, & adverse reactions.
-
Marie Warrer Munch
Review 2: "Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results"
This reliable study suggests four antivirals have no effect on important clinical outcomes in hospitalized COVID-19 patients. While the randomized control trial is thorough, reviewers note missing descriptions of study protocol, patient eligibility, & adverse reactions.
-
Alberto Borobia, Antonio J Carcas
Review 1: "Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results"
This reliable study suggests four antivirals have no effect on important clinical outcomes in hospitalized COVID-19 patients. While the randomized control trial is thorough, reviewers note missing descriptions of study protocol, patient eligibility, & adverse reactions.
-
Strength of evidence
Reviewers: Alberto Borobia, Antonio J Carcas (La Paz University Hospital) | 📗📗📗📗 ◻️
Marie Warrer Munch (Rigshospitalet) | 📗📗📗📗 ◻️
Stephen Shiboski (UCSF) | 📗📗📗📗 ◻️
Emily Walsh (Kaiser Permanente) | 📒📒📒 ◻️◻️ -
SciScore for 10.1101/2020.10.15.20209817: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Analyses used SASv9.4 and Rv4.02. OVERSIGHT AND FUNDING The trial is registered (ISRCTN83971151, NCT04315948), with protocol approved by local and WHO ethics committees. Randomization RESULTS In 405 hospitals in 30 countries 11,266 adults were randomized, with 2750 allocated Remdesivir Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the …
SciScore for 10.1101/2020.10.15.20209817: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Analyses used SASv9.4 and Rv4.02. OVERSIGHT AND FUNDING The trial is registered (ISRCTN83971151, NCT04315948), with protocol approved by local and WHO ethics committees. Randomization RESULTS In 405 hospitals in 30 countries 11,266 adults were randomized, with 2750 allocated Remdesivir Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04315948 Recruiting Trial of Treatments for COVID-19 in Hospitalized Adults NCT04385095 Recruiting Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-1... NCT04492475 Recruiting Adaptive COVID-19 Treatment Trial 3 (ACTT-3) ISRCTN83971151 NA NA Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
-
